Compare TCBK & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBK | BCRX |
|---|---|---|
| Founded | 1975 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1995 | 1995 |
| Metric | TCBK | BCRX |
|---|---|---|
| Price | $47.11 | $8.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $53.80 | $20.82 |
| AVG Volume (30 Days) | 140.5K | ★ 4.0M |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | 6.94 | ★ 381.40 |
| EPS | ★ 3.70 | 1.21 |
| Revenue | ★ $53,445,000.00 | $25,186,000.00 |
| Revenue This Year | $11.70 | N/A |
| Revenue Next Year | $4.47 | $12.55 |
| P/E Ratio | $13.04 | ★ $7.00 |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $35.20 | $6.00 |
| 52 Week High | $53.18 | $11.31 |
| Indicator | TCBK | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 69.72 |
| Support Level | $46.76 | $7.95 |
| Resistance Level | $51.11 | $8.68 |
| Average True Range (ATR) | 1.44 | 0.33 |
| MACD | -0.32 | 0.12 |
| Stochastic Oscillator | 18.47 | 81.19 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.